The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Molecular Cancer Research

PI Lars Rönnstrand


The receptor tyrosine kinases KIT and FLT3 are both important regulators of development and maintenance of a number of different cell types. Deregulation of these receptors by mutations has been implicated in various human malignancies, including akut myeloid leukemia and melanoma. The signaling pathways activated by the oncogenic mutants are to some extent unique and different from wild-type receptor signaling. These molecules are potential novel targets for pharmacological intervention.

Heavily enlarged image of Microarray on black background.

Our research

By a broad mass spectrometry based approach on whole cells we are in the process of identifying additional such proteins and their phosphorylation status. Finally, patients with certain subtypes of malignant melanoma carry activating mutations in KIT that is driving the disease. Given the functional relation between KIT and the transcription factor MITF, we are investigating the molecular mechanisms behind the KIT-mediated regulation of MITF.

Heavily enhanced image of cells in immunofluorescence.
Picture of Lars Rönnstrand sitting in his office chair.

Lars Rönnstrand

Phone: +46 46 222 64 54
Mail: lars [dot] ronnstrand [at] med [dot] lu [dot] se

Personal research portal page

Team Members

Saleena Younus Kunju

Özge Tatli

Jianmin Sun

Johanna Verngren

Click on the name to visit their personal research portal page.